Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.

Alexa B Kimball,Gregor B E Jemec,Afsaneh Alavi,Ziad Reguiai, Alice B Gottlieb,Falk G Bechara, Carle Paul,Evangelos J Giamarellos Bourboulis,Axel P Villani,Andreas Schwinn,Franziska Ruëff,Larisha Pillay Ramaya,Adam Reich,Ines Lobo,Rodney Sinclair,Thierry Passeron,Antonio Martorell,Pedro Mendes-Bastos,Georgios Kokolakis,Pierre-Andre Becherel,Magdalena B Wozniak,Angela Llobet Martinez,Xiaoling Wei,Lorenz Uhlmann,Anna Passera,Deborah Keefe,Ruvie Martin, Clarice Field,Li Chen,Marc Vandemeulebroecke,Shoba Ravichandran,Elisa Muscianisi

Lancet (London, England)（2023）

Cited 42|Views39
No score
Abstract
Novartis Pharma.
More
Translated text
Key words
secukinumab,sunshine,moderate-to-severe,placebo-controlled,double-blind
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined